MedTrace Logo

A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt

NCT04106323 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-03-12

No results posted yet for this study

Summary

Hemophilia A and B are bleeding disorders caused by deficiency of factor VIII and IX, respectively. The deficiency of one of these coagulation factors is due to a mutation on the X chromosome. Accordingly replacement of the deficient factor is currently the main treatment for these disorders. The most disappointing complication of replacement therapy in hemophilia is the development of inhibitors. Unlike haemophilia , inhibitor development in patients with V Willebrand's Disease (VWD) is a rare complication of treatment. Studies on inhibitors whether on hemophilia or VWD are limited in our region.

This study aims to

1. To estimate the frequency of factor inhibitors in hemophilia and VWD patients in our region.
2. To investigate modifiable risk factors associated with development of inhibitors in both diseases.
3. To correlate the level of inhibitor with the clinical presentation of the patients.
4. To assess influence of factor inhibitors on quality of life in patients who developed factor inhibitors in both diseases.

Conditions

  • Hemophilia
  • Von Willebrand Diseases
  • Christmas Disease

Sponsors & Collaborators

  • Safaa AA Khaled

    lead OTHER

Principal Investigators

  • Howaida A. Nafady, Prof. · Assiut University Hospial

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-10
Primary Completion
2020-11-10
Completion
2021-08-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106323 on ClinicalTrials.gov